Therapeutics News and Research

RSS

Data from Novogen inflammatory bowel disease drug Phase I clinical trial shows promise

A recently completed Phase 1 clinical trial of an investigational drug to treat inflammatory bowel disease has demonstrated rapid absorption indicating potential for development as an oral therapy.

6 Mar 2006

Pfizer acquires worldwide rights to Exubera

Pfizer has announced that it has acquired the sanofi-aventis worldwide rights to Exubera (inhaled human insulin). Pfizer received approval last month to market Exubera in the United States and the European Union for the treatment of adults with type 1 and type 2 diabetes.

1 Mar 2006

Ancient DNA helps unearth potential hemophilia therapy

A cut can be life-threatening for people with hemophilia, whose bodies don't produce enough of a protein that prevents prolonged bleeding.

1 Mar 2006

Two drug giants team up to develop new bird flu therapy

Two major drug companies have teamed up in order to develop a treatment for pandemic flu strains.

22 Feb 2006

M. D. Anderson Cancer Center to investigate CTCE-9908 chemokine CXCR4 antagonist

Chemokine Therapeutics has announced that it has entered into an agreement with The University of Texas M. D. Anderson Cancer Center of Houston, Texas to study the Company's lead anti-cancer compound, CTCE-9908, a chemokine CXCR4 antagonist.

21 Feb 2006

Breakthrough anti-inflammatory treatment

Scientists from the Garvan Institute of Medical Research have developed what could be the next big blockbuster treatment for inflammatory diseases such as rheumatoid arthritis and asthma.

21 Feb 2006

New insight into pathogenic mechanisms underlying basal-like breast cancers

Basal-like breast cancers (BLC) are highly aggressive tumors with a relatively poor prognosis that account for approximately 15% of sporadic human breast cancer.

16 Feb 2006

Stealthyx Therapeutics and Cancer Research Technology announce co-development partnership for tumour-targeted therapy

Cancer Research Technology (CRT), the specialist oncology development and commercialisation company, and Stealthyx Therapeutics, the disease targeting drug company spin out of Queen Mary, University of London have entered into an agreement to co-develop Stealthyx’s proprietary drug delivery platform, Prothyx.

16 Feb 2006

Chink in cancer's armor

Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.

13 Feb 2006

Another step forward in the battle against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy; antibiotics; the search for new remedies against bacterial infections is in high gear.

12 Feb 2006

Nod1 found to control tumor growth in certain breast cancers

This protein was previously thought to play a role solely in the innate immune system's response to bacterial infection. In the new study, which will be published on-line by the Proceedings of the National Academy of Sciences

12 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Source of crucial immune cell in the skin discovered - may lead to tumor immunotherapy

Mount Sinai School of Medicine researchers have identified the precursors of cells in the skin that are part of the first line of defense against invading pathogens. The study appears on Nature Immunology's website.

7 Feb 2006

Advance in the fight against bacterial infections

Bacterial infections can strike anyone, and they can sometimes be fatal. Because more and more bacteria are becoming resistant to the pre-eminent remedy - antibiotics - the search for new remedies against bacterial infections is in high gear.

2 Feb 2006

Angina drug finally gets the ok

U.S. regulators have granted approval for the drug Ranexa in the treatment of chronic angina.

31 Jan 2006

New inhaled drug for diabetics an alternative treatment option for some

The Food and Drug Administration (FDA) in the U.S. has given it's approval for the sale of a new drug to treat diabetes.

29 Jan 2006

Study may provide new hope for cancer patients

New study by Mount Sinai researchers may lead to improved stem cell therapies for patients with compromised immune systems due to intensive cancer therapy or autoimmune disease. The study is published in this week's issue of Cell.

27 Jan 2006

New biochip predicts evolution of inflammatory bowel disease

The treatment of inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, has very high costs and can include admissions and surgical interventions. Until now, there was no precise tools to predict the evolution and prognosis of these diseases.

26 Jan 2006

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids (RNA).

25 Jan 2006

First-of-its-kind study in heart attack patients seeks to prevent heart failure with stem cells

University of Rochester Medical Center researchers have announced the launch of a study that will examine whether transplanted stem cells can be safely used to treat damaged heart muscle in patients just after their first heart attack.

23 Jan 2006